<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568308</url>
  </required_header>
  <id_info>
    <org_study_id>PR88302</org_study_id>
    <nct_id>NCT00568308</nct_id>
  </id_info>
  <brief_title>Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma</brief_title>
  <acronym>PATHWAY</acronym>
  <official_title>A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Progen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Progen Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if PI-88 is effective and safe in patients who have
      had surgery to remove primary liver cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary liver cancer (hepatocellular carcinoma or HCC) is the fifth most common cancer
      worldwide. Surgery to remove the tumour remains the principal form of treatment for liver
      cancer, however recurrence of the disease after surgery is common and survival after
      recurrence is poor. At the moment there is no recommended standard treatment for HCC
      immediately after the tumour has been removed surgically. PI-88 is a new experimental drug
      which blocks the growth of new blood vessels in tumours to stop the tumour growing (starves
      it of food) and also stops tumour cells spreading. Previous experience with PI-88 has shown
      it has been well tolerated and has shown some benefit in delaying the time it takes for the
      hepatocellular carcinoma to reappear after surgery. The purpose of this study is to determine
      if PI-88 is effective and safe in patients who have had surgery to remove primary liver
      cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Commercial decision to discontinue the study
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>End of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Primary Liver Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PI-88</intervention_name>
    <description>160mg subcutaneous injection</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Histologically-proven primary hepatocellular carcinoma with curative resection
             performed in the 4 - 6 weeks prior to randomisation.

          -  ECOG performance status 0 to 2

          -  Child Pugh classification A or B

        Key Exclusion Criteria:

          -  Any evidence of tumour metastasis or co-existing malignant disease

          -  Any prior recurrence of HCC or any liver resection prior to the most recent procedure

          -  History of prior HCC therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronnie TP Poon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hong Kong, Queen Mary Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>United States of America</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Australia</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canada</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Italy</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaysia</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spain</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taiwan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thailand</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.progen-pharma.com</url>
    <description>Progen Pharmaceuticals Website</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>June 13, 2011</last_update_submitted>
  <last_update_submitted_qc>June 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Liz Wilson</name_title>
    <organization>Progen Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>PI-88</keyword>
  <keyword>Phase III</keyword>
  <keyword>Adjuvant Therapy</keyword>
  <keyword>Hepatoma</keyword>
  <keyword>Liver Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

